BioCentury
ARTICLE | Clinical News

AN2898: Preliminary Phase IIa data

December 19, 2011 8:00 AM UTC

Preliminary data from a double-blind, Australian Phase IIa trial in 46 patients with mild to moderate atopic dermatitis showed that topical twice-daily 2% AN2728 and twice-daily 1% AN2898 for 6 weeks...